Recombinant monoclonal antibody to Human IgE. Omalizumab is a recombinant DNA-derived humanized IgG1k monoclonal antibody that specifically binds to free human immunoglobulin E (IgE) in the blood and interstitial fluid and to membrane-bound form of IgE (mIgE) on the surface of mIgE-expressing B lymphocytes. Unlike an ordinary anti-IgE antibody, omalizumab does not bind to IgE that is already bound by the high affinity IgE receptor (FcεRI) on the surface of mast cells, basophils, and antigen-presenting dendritic cells. IgE is commonly involved in type I hypersensitivity, which manifests the most prevalent allergic diseases. It has been estimated that as high as 20 to 40% of the populations who live a western lifestyle in economically advanced countries are affected by allergy and seek medical help. In the U.S., 8% of adults and 10% of children have asthma. While allergy occurs more frequently in individuals with higher serum IgE levels, such a correlation is only statistical and not absolute. Some allergic individuals have very low serum IgE, and some people with very high IgE have no allergic problems.
Figure 1 Comparison of effect of treatment with omalizumab and placebo on changes in absolute and % predicted forced expiratory volume in 1 s (FEV1) between baseline and times A and B.
Bars represent the median and interquartile range. Mann–Whitney U-Test used for comparison.
Pillai, P., Chan, Y. C., Wu, S. Y., Ohm-Laursen, L., Thomas, C., Durham, S. R., ... & Corrigan, C. J. (2016). Omalizumab reduces bronchial mucosal IgE and improves lung function in non-atopic asthma. European Respiratory Journal, 48(6), 1593-1601.
Figure 2 A single IgE mutation prevents omalizumab binding.
SPR-binding assays with immobilized omalizumab.
Pennington, L. F., Tarchevskaya, S., Brigger, D., Sathiyamoorthy, K., Graham, M. T., Nadeau, K. C., ... & Jardetzky, T. S. (2016). Structural basis of omalizumab therapy and omalizumab-mediated IgE exchange. Nature communications, 7, 11610.
Figure 3 E2_79 and omalizumab bind to both WT and Cys-335 IgE-Fc proteins.
A , E2_79 binds to both WT IgE-Fc ( open circles , solid line ) and Cys-335 IgE-Fc ( filled circles , dashed line ) in an ELISA assay. IgE-Fc proteins were plated and incubated with E2_79 at the indicated concentrations, and E2_79 binding was detected with an anti-His tag antibody. B , omalizumab binds to both WT IgE-Fc ( open circles , solid line ) and Cys-335 IgE-Fc ( filled circles , dashed line ) in an ELISA assay. IgE-Fc proteins were plated and incubated with omalizumab, and omalizumab binding was detected with a polyclonal anti-IgG antibody. C and D , side ( C ) and top ( D ) views of the omalizumab-binding region on the IgE-Fc C ⑀ 3 domain. The main chain conformation of the IgE-Fc Cys-335 structure and the disulfide bond at residue 335 are shown in magenta , whereas residues mapped to the omalizumab binding region are shown in stick representation . Omali- zumab binding interactions have been mapped to IgE residues 421– 432 including the FG loop residues 424 – 426 (HLP) that lie within the Fc ⑀ RI ␣ binding interface (33). Despite the conformational restriction imposed by the Cys-335 disulfide, the omalizumab epitope remains accessible to binding.
Wurzburg, B. A., Kim, B., Tarchevskaya, S. S., Eggel, A., Vogel, M., & Jardetzky, T. S. (2012). An engineered disulfide bond reversibly traps the IgE-Fc3-4 in a closed, non-receptor binding conformation. Journal of biological chemistry, jbc-M112.
Figure 4 Omalizumab has no inhibitory effect on anti-IgE-induced degranulation.
(a) Freshly isolated human skin mast cells were coincubated with or without omalizumab (10 ug/mL) for 24 h or with DARPin Fc (100 pmol/mL) for 1 h as positive control for FceRI-FccRIIb cross linking. Mast cells were then activated with anti-IgE (1 ug/mL) for 1 h and histamine release determined. Results are expressed as mean SEM histamine release (% total) of three independent experiments. Panel (b) shows peripheral blood-derived monocytes from healthy donors that were coincubated with or without omalizumab (10 ug/mL) for 1 h and then activated using anti-IgE (5 ug/mL) for another hour to induce degranulation. Results are expressed as mean SEM histamine release (% total) of five independent experiments.
Gericke, J., Ohanyan, T., Church, M. K., Maurer, M., & Metz, M. (2015). Omalizumab may not inhibit mast cell and basophil activation in vitro. Journal of the European Academy of Dermatology and Venereology, 29(9), 1832-1836.
Figure 5 Inducible expression of IgE BCR on IMIGEC cells - a cell reporter for membrane IgE EMPD crosslinking.
Upper panel: Surface expression of membrane IgE BCR on IMIGEC cells was measured by flow cytometry at different time points of dox incubation (0-48 h, x-axis) with mABs recognizing various regions of the IgE BCR (MFI, y-axis) or respective isotype controls. The right part of the plot shows expression kinetics after 24 h dox treatment followed by 24 h dox withdrawal. Pooled data of 3 biological replicates are shown as mean ± SD. Lower panels: Exemplary histograms and MFI values (FL-2/PE channel) after 18 h are shown.
Oskar, W. (2016). Quantitative in vitro and in vivo models to assess human IgE B cell receptor crosslinking by IgE and EMPD IgE targeting antibodies. Journal of Immunological Methods.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Afuco™ Anti-IGHE ADCC Recombinant Antibody (Omalizumab), ADCC EnhancedThis product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to Human IgE. Omalizumab is a recombinant DNA-derived humanized IgG1k monoclonal antibody that specifically binds to free human immunoglobulin E (IgE) in the blood and interstitial fluid and to membrane-bound form of IgE (mIgE) on the surface of mIgE-expressing B lymphocytes. Unlike an ordinary anti-IgE antibody, omalizumab does not bind to IgE that is already bound by the high affinity IgE receptor (FcεRI) on the surface of mast cells, basophils, and antigen-presenting dendritic cells. IgE is commonly involved in type I hypersensitivity, which manifests the most prevalent allergic diseases. It has been estimated that as high as 20 to 40% of the populations who live a western lifestyle in economically advanced countries are affected by allergy and seek medical help. In the U.S., 8% of adults and 10% of children have asthma. While allergy occurs more frequently in individuals with higher serum IgE levels, such a correlation is only statistical and not absolute. Some allergic individuals have very low serum IgE, and some people with very high IgE have no allergic problems.
CAT | Product Name | Application | Type |
---|---|---|---|
NABL-092 | Recombinant Anti-human IGHE VHH Single Domain Antibody | WB, ELISA, IHC, FC, FuncS | Llama VHH |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-755 | Anti-IGHE Recombinant Antibody (Ligelizumab) | Neut, ELISA, IF, IP, FuncS, FC, ICC | IgG1 - kappa |
CAT | Product Name | Application | Type |
---|---|---|---|
AGTO-L061R | anti-IGHE immunotoxin (Fab)-RTA | Cytotoxicity assay, Functional assay |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-256CQ | Human Anti-IGHE Recombinant Antibody (TAB-256CQ) | Agonist | Human IgG2, κ |
TAB-257CQ | Human Anti-IGHE Recombinant Antibody (TAB-257CQ) | Agonist | Human IgG2, κ |
TAB-256CQ-S(P) | Human Anti-IGHE Recombinant Antibody; scFv Fragment (TAB-256CQ-S(P)) | ELISA, FC, WB | Human scFv |
TAB-257CQ-S(P) | Human Anti-IGHE Recombinant Antibody; scFv Fragment (TAB-257CQ-S(P)) | ELISA, FC, WB | Human scFv |
TAB-258CQ-S(P) | Human Anti-IGHE Recombinant Antibody; scFv Fragment (TAB-258CQ-S(P)) | ELISA, FC, WB | Human scFv |
CAT | Product Name | Application | Type |
---|---|---|---|
HPAB-0168-LSX | Mouse Anti-IGHE Recombinant Antibody (clone MaE10) | ELISA, FC | Mouse IgG1 |
HPAB-0169-LSX | Mouse Anti-IGHE Recombinant Antibody (clone MAE11) | ELISA, FC, SPR | Mouse IgG2 |
VS-0322-LC94 | Rabbit Anti-IGHE Recombinant Antibody (clone rMaE11) | Block, ELISA | |
VS-0322-LC96 | Rabbit Anti-IGHE Recombinant Antibody (clone rTES-C21) | Block, ELISA | |
VS3-WK1515 | Mouse Anti-IGHE Recombinant Antibody (VS3-WK1515) | WB, ELISA | Mouse IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
HPAB-0168-LSX-S(P) | Mouse Anti-IGHE Recombinant Antibody (clone MaE10); scFv Fragment | ELISA, FC | Mouse scFv |
HPAB-0169-LSX-S(P) | Mouse Anti-IGHE Recombinant Antibody (clone MAE11); scFv Fragment | ELISA, FC | Mouse scFv |
HPAB-0170-LSX-S(P) | Human Anti-IGHE Recombinant Antibody (clone 235-5.2); scFv Fragment | ELISA, FC | Humanized scFv |
HPAB-0171-LSX-S(P) | Human Anti-IGHE Recombinant Antibody; scFv Fragment (HPAB-0171-LSX-S(P)) | ELISA, RIA | Human scFv |
HPAB-0028-YJ-S(P) | Human Anti-IGHE Recombinant Antibody (clone E26); scFv Fragment | ELISA | Humanized scFv |
CAT | Product Name | Application | Type |
---|---|---|---|
HPAB-0168-LSX-F(E) | Mouse Anti-IGHE Recombinant Antibody (clone MaE10); Fab Fragment | ELISA, FC | Mouse Fab |
HPAB-0169-LSX-F(E) | Mouse Anti-IGHE Recombinant Antibody (clone MAE11); Fab Fragment | ELISA, FC | Mouse Fab |
HPAB-0170-LSX-F(E) | Human Anti-IGHE Recombinant Antibody (clone 235-5.2); Fab Fragment | ELISA, FC | Humanized Fab |
HPAB-0171-LSX-F(E) | Human Anti-IGHE Recombinant Antibody; Fab Fragment (HPAB-0171-LSX-F(E)) | ELISA, RIA | Human Fab |
HPAB-0028-YJ-F(E) | Human Anti-IGHE Recombinant Antibody (clone E26); Fab Fragment | ELISA | Humanized Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
AFC-TAB-007 | Afuco™ Anti-IGHE ADCC Recombinant Antibody (Omalizumab), ADCC Enhanced | ELISA, IP, FC, FuncS, Neut | ADCC enhanced antibody |
AFC-TAB-255 | Afuco™ Anti-IGHE ADCC Recombinant Antibody (Quilizumab), ADCC Enhanced | IP, IF, FuncS, FC, Neut | ADCC enhanced antibody |
AFC-TAB-755 | Afuco™ Anti-IGHE ADCC Recombinant Antibody (Ligelizumab), ADCC Enhanced | Neut, ELISA, IF, IP, FuncS, FC | ADCC enhanced antibody |
There are currently no Customer reviews or questions for TAB-007. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.